These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28211641)

  • 1. Risk of malignancy in psoriatic patients: Our clinical experience.
    Magnano M; Loi C; Sechi A; Sgubbi P; Raone B; Patrizi A; Bardazzi F
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28211641
    [No Abstract]   [Full Text] [Related]  

  • 2. Rate of serious infection in patients who are prescribed systemic biologic or nonbiologic agents for psoriasis: A large, single center, retrospective, observational cohort study.
    Carneiro C; Bloom R; Ibler E; Majewski S; Sable KA; Guido NJ; Day J; Nocadello S; Florek AG; West DP; Nardone B
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28796405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching biological agents for psoriasis in secondary care: a single-centre, retrospective, open-label study.
    Woo WA; Waite A; Rustin MH; McBride SR
    Br J Dermatol; 2014 Apr; 170(4):989-90. PubMed ID: 24298875
    [No Abstract]   [Full Text] [Related]  

  • 4. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
    Henderson Berg MH; Carrasco D
    J Drugs Dermatol; 2017 Jul; 16(7):695-698. PubMed ID: 28697222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatments in psoriasis.
    Carrascosa JM
    Med Clin (Barc); 2017 Aug; 149(4):157-159. PubMed ID: 28476451
    [No Abstract]   [Full Text] [Related]  

  • 6. The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
    Tabolli S; Giannantoni P; Paradisi A; Abeni D
    Br J Dermatol; 2015 Jul; 173(1):256-8. PubMed ID: 25422080
    [No Abstract]   [Full Text] [Related]  

  • 7. Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development.
    Kirsten N; Bulai Livideanu C; Richard MA; Konstantinou MP; Khemis A; Balluteaud C; Goujon C; Beylot-Barry M; Paul C;
    Br J Dermatol; 2016 Sep; 175(3):636-8. PubMed ID: 27038074
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.
    Farhangian ME; Feldman SR
    Am J Clin Dermatol; 2015 Aug; 16(4):285-294. PubMed ID: 25963062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects.
    Sutherland A; Power RJ; Rahman P; O'Rielly DD
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):923-35. PubMed ID: 27266955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
    Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
    J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of malignancy associated with cyclosporin use in psoriasis.
    Paul C; Hornig F
    Dermatology; 1999; 198(3):320-1. PubMed ID: 10419287
    [No Abstract]   [Full Text] [Related]  

  • 12. Fumaric acid esters as a suitable first-line treatment for severe psoriasis: an Irish experience.
    Heelan K; Markham T
    Clin Exp Dermatol; 2012 Oct; 37(7):793-5. PubMed ID: 22548419
    [No Abstract]   [Full Text] [Related]  

  • 13. [Body-weight changes in psoriatic patients on systemic treatment].
    Forien M; Mahé E; Sin C; Marchal A; Sigal ML
    Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
    [No Abstract]   [Full Text] [Related]  

  • 14. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
    Asgari MM; Ray GT; Geier JL; Quesenberry CP
    J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.
    Kimball AB; Schenfeld J; Accortt NA; Anthony MS; Rothman KJ; Pariser D
    Br J Dermatol; 2015 Nov; 173(5):1183-90. PubMed ID: 26265015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and systemic therapies administered to first-time patients at a tertiary psoriasis outpatient clinic.
    Bonifati C; Graceffa D; Lora V; Maiani E
    G Ital Dermatol Venereol; 2016 Dec; 151(6):596-602. PubMed ID: 26505567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective claims analysis confirms the cost of most biologic agents for psoriasis is increasing more rapidly than medical inflation.
    Patel D; Svoboda R; Maczuga S; Foulke GT; Helm M
    J Am Acad Dermatol; 2023 Feb; 88(2):490-493. PubMed ID: 35752276
    [No Abstract]   [Full Text] [Related]  

  • 18. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
    Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
    Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of biologics in the treatment of hidradenitis suppurativa: a review of the Henry Ford Hospital experience.
    Zhang J; Reeder VJ; Hamzavi IH
    Br J Dermatol; 2014 Dec; 171(6):1600-2. PubMed ID: 24931223
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
    Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
    Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.